Search Results
Habitual Diet and Avocado Trial
This study aims to evaluate the effect of providing one avocado per day for consumption over a six month period on established health parameters, including visceral adiposity, hepatic lipid content, markers of metabolic syndrome and high sensitivity C-reactive protein (hsCRP), compared to habitual diet. The primary aim of this study is to determine whether providing one avocado per day for consumption for six months will produce a greater decrease in visceral adiposity as measured by magnetic resonance imaging (MRI) in Americans with an increased waist circumference as compared to habitual diet.
not currently eating >2 avocados per month
increased waist circumference (35+ inches for women, 40+ inches for men)
not willing to undergo MRI scans
unstable medical conditions
lost/gained 10 or more pounds in past year
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC) once monthly for at least 12 months. Subjects entering CSL312_3002 will be from 3 sources: • Subjects who participated in Study CSL312_2001 • Subjects who participated in Study CSL312_3001 • CSL312-naïve HAE subjects who have not participated in either of the above studies
During the study, you will be expected to self-administer the study medication by injection under the skin once a month, complete a daily diary, provide blood and urine samples, complete questionnaires, undergo physical exams and have your vital signs recorded. You will visit the site 12 times.
$80.00 plus travel reimbursement
Male or female
Diagnosed with clinically confirmed C1-INH HAE
Experienced ≥ 3 HAE attacks during the 3 months before Screening, as documented in the subject's medical record.
Aged ≥ 12 at the time of providing written informed consent or assent for minors
Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis against HAE attacks at least 2 weeks before the first day of the Run-in Period.
Use of mAbs such as lanadelumab (Takhzyro®) 3 months before the first day of the Run-in Period.
Female subjects’ use of estrogen-containing medications with systemic absorption (eg, oral contraceptive or hormonal replacement therapy within 4 weeks prior to the Run-in Period).
Female or male subjects who are fertile and sexually active not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 3 months after receipt of the last dose of CSL312.
Impact of Mental Illness on Blame Attribution and Perception of Dangerousness in Violent Crime Offenders: Implications for Sentencing
This study will be used for an undergraduate honors thesis, focused on mental health’s impact on perceived blameworthiness and dangerousness of violent crime offenders and sentencing suggestions for said offenders. In this study, participants will read a vignette about a crime (homicide or assault) being committed. After reading this scenario, participants will answer 4 questions about the individual who committed the crime. These questions will ask about blame attribution, sentencing suggestions, danger perception and likelihood of reoffending. The data will be analyzed through quantitative techniques.
Participants will read a vignette about a crime (homicide or assault) being committed. After reading this scenario, participants will answer 4 questions about the individual who committed the crime. These questions will ask about blame attribution, sentencing suggestions, danger perception and likelihood of reoffending. Participants will then answer one question about their gender and one question about the school year.
Undergraduate students at Pennsylvania State University Park under the age of 18
PSCI# 19-005 EA9161
The is a drug study to compare the progression free survival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.
pt will either get ibrutinib and obinutuzumab, plus venetoclax for up to 19 months or will get ibrutinib and obinutuzumab until doctor decides disease is getting worse or the side effects become too severe. After 19 cycles completed, doctor will follow condition every 90 days until progression and watch for side effects. They will check pt every 3 months for 2 years. After that, they will check pt every 6 months for 3 years. After that, they will check pt every 12 months for 5 years
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy
Biobehavioral Health Risk and Resilience in College Students (PSU THRIVE Study)
This protocol is designed to examine biobehavioral health risks, resilience, grit, forgiveness and well-being in college students.
18 to 24 years of age
English is a primary language
Under age of 18 years
Over age of 24 years
Not comfortable speaking English
Developing a Recommendation System for Local Community Events
In this study, we investigate a recommender system for public, local events in Centre County, PA. Currently, there is no platform that aggregates all the events that take place in a community. The data is fragmented among many platforms and it can be difficult for people to find interesting things to do. Participants will interact with our software system and discuss their experiences through a survey and/or interview.
Must be a University Park student or local resident of Centre County
Persons who do not live in Centre County, PA
PSCI 24-015 S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY
To see if participants with early stage triple negative breast cancer randomized to receive anthracycline-free, taxane-platinum neoadjuvant chemotherapy with pembrolizumab have a better breast cancer event-free survival (BC-EFS) compared to participants randomized to taxane-platinum-anthracycline neoadjuvant chemotherapy with pembrolizumab.
keep all study appointments report to your study team any side effects or any changes in medication
Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or MRI within 49 days prior to randomization.
Participants must not have metastatic disease
Participants must not have received prior systemic therapy or radiation therapy
Participants must be ≥ 18 years old.
Participants must not have a prior or concurrent malignancy
Participants must not have received a live vaccine within 30 days prior to randomization.
Participants must not have active autoimmune disease
Participants must not have severe or active infections
Behind virtual world building: Studying virtual reality environmental characteristics
This is a user study to investigate the environmental characteristics of virtual reality (VR). This study will provide empirical evidence of the essential characteristics based on users’ feedbacks. During your visit, you will receive a brief training about using a VR headset and navigating in the virtual environment. After the training, you will explore the virtual environment, complete tasks in VR, and answer questions regarding your feelings to our VR application.
healthy participants
students under 18
students with contagious disease
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Participants in this study will receive a drug called ribociclib with the endocrine therapy of your physician’s choice. Ribociclib is taken as a pill. Endocrine therapy is taken as a pill or given as a shot. You will have tests, exams and procedures that are part of your regular care and for study purposes. Also, as part of routine care, you will be checked every 4 to 12 weeks to make sure your cancer hasn’t come back. You will receive ribociclib combined with endocrine therapy for up to 3 years. After that you will continue endocrine therapy alone for another 2 years (5 years total) as part of your regular care.
Participants will be required to: - receive ribociclib along with standard endocrine therapy drugs - have blood drawn - imaging scans (CT, PET-CT, bone scans, mammograms, MRI) - keep a medication diary - optional biopsy - ECG-a test that looks at the way your heart beats - ECHO-a test that looks at the way your heart pumps
Male or female age ≥ 18 years at the time of consent.
ECOG Performance Status of 0-1 within 28 days prior to registration.
If patient is receiving tamoxifen or toremifene, a washout period of 28 days prior to registration is required.
Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory.
Patient who has received prior CDK4/6 inhibitor for recurrent disease. Patients who received a CDK4/6 inhibitor in the adjuvant setting may participate if they have been off therapy for at least 1 year prior to diagnosis of recurrent disease.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Pregnant or breastfeeding or planning to become pregnant during the trial
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety
The Experiences of Asexual Individuals in Health and Sexual Education Classes: Influences on Identity, Body Image, Personal Health, and Patient-Provider Relationships
This project explores the experiences of asexual individuals in health and sexual education classes. Specifically, we are interested in the structure of the courses and the extent to which LGBTQIA+ identities were included in the curriculum. Additionally, we are interested in ways health and sexual education classes have since influenced how asexual individuals view and feel about their bodies, as well as how they approach their personal health. Individuals currently identifying as asexual will be surveyed about their experiences and will have the change to provide recorded interviews if desired.
Participants will be asked to complete an online survey that is expected to take 30-40 minutes. Participants also have the opportunity to elaborate on their survey responses during a recorded Zoom interview.
Participants may enter a raffle to win one of 10 Amazon.com giftcards
Over the age of 18
Took a health/sexual education class in the U.S since the year 2000
Currently identifies as asexual (or an asexual sub-identity)
Under the age of 18
Did not take a health/sexual education class in the U.S since the year 2000
Does not currently identify as asexual (or an asexual sub-identity)
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.
Phase II *propranolol twice a day. *pembrolizumab by an infusion every 3 weeks. *May receive treatment with pembrolizumab and propranolol for up to 24 months from the time they began treatment with the combination. Procedures to be done:. A medical history A physical exam ECOG Performance Status Perceived Stress Scale questionnaire An assessment of tumor by scan. Scans may include: o Computed tomography (CT), with or without contrast. o Magnetic resonance imaging (MRI) or head CT with IV contrast Blood tests: o Approximately 2 tablespoons for routine testing, such as a complete blood count and a comprehensive metabolic panel Pregnancy test Urinalysis Electrocardiogram A sample of tumor from a previous biopsy or sample taken Phase 1 portion of the study, these evaluations/tests will also occur on Day 8 of Cycle 1 Review concomitant medications. Physical Exams ECOG Performance Status Perceived Stress Scale questionnaire Blood tests: o Every 3 weeks o At 3 weeks and 6 months or discontinuation of treatment (whichever comes sooner) and at disease progression o Every 3 weeks: Approximately 1 tablespoon for tests that monitor your blood sugar levels and thyroid function o Every week for the first 6 weeks then every cycle for another 6 weeks Assessment of cancer by CT or MRI. These assessments will be performed every 12 weeks(± 14 days). The first assessment will be after completing Cycle 4. If their cancer is found to be improving, repeat the CT and MRI scans in about 12 weeks. EKG: Once treatment begins, this will be done every cycle prior to receiving pembrolizumab for the first 5 cycles. Adverse events Tumor Biopsy: A tumor biopsy (only in phase II) will be obtained at the 12 weeks after initiation of treatment.Tumor biopsy will be optional for phase II patients.. Safety Follow-Up: After all study treatment has stopped, end of treatment visit, which will be approximately 30 days after their last dose of study drug or before starting a new treatment Medical History: Concomitant medications complete physical examination ECOG Performance Status Perceived Stress Scale assessment Adverse events Survival status Blood tests: o Follow- Up Phase 3 Month and 6 Month Follow- up After Treatment blood collected. The following assessments will be performed at 3 months and 6 months after the safety follow-up visit. Review concomitant medications Physical examination ECOG Performance Status Adverse events Survival Status Blood tests: CT of chest, abdomen and pelvis, or other areas as needed Long Term Survival Follow- Up: After your 3 month and 6 month follow up visits or if they progress, will be contacted every 6 months (±30 days)
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
Advancing the use of immersive virtual environments to study the effects of racism on eating behavior in an Asian American population
During the COVID-19 pandemic, Asian Americans have faced a rise in overt racism, with thousands of hate incidents reported. This has had a bigger impact on young Asian American adults, leading to emotional distress and health problems. A theory by Harrell suggests that experiencing racial discrimination can harm mental and physical well-being due to stress. Past studies have shown a connection between racial discrimination stress and health issues like obesity and mental disorders. However, there's a need to understand the cultural and emotional factors involved. This research aims to explore how racial discrimination affects Asian Americans' food choices by looking at stress responses and cultural influences. Using surveys, experiments, psychophysiology, and virtual reality, the study will investigate how cultural identity affects stress reactions and subsequent food decisions after racial discrimination experiences.
Hello, We are recruiting Asian Americans with Japanese, Chinese, or Korean heritage for a paid research study. We want to understand how racism affects food choice in a virtual reality (VR) environment. To participate in this study, you will need to complete an informed consent form, and answer questions prior to your arrival at the lab. You will have to come to the lab to watch a video of anti-Asian racism incidents that happened during the COVID-19 pandemic, and answer questions before and after the video. Last, you will make food choices in the VR environment. Participation will require three hours or more of fasting before arrival at the lab. You will be paid $25 in a gift card for your participation. If you come to the lab but do not complete the study, you will still be paid. Please continue to the next page to read the informed consent if you are interested in participating. If you are not, please exit this page. https://redcap.link/lp1wq7uu
$25 Amazon gift card
Aged between 18 and 21 at the start of the study
Born in the US or lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for at least 3 hours prior to the start of the study
Not aged between 18 and 21 at the start of the study
Not born in the US or not having lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for less than 3 hours prior to the start of the study
Has epilepsy or a cognitive disability
Effects of atherosclerosis on the autonomic responses to systemic nitric oxide
This research looks at whether atherosclerosis, which is the buildup of fatty deposits in the arteries, affects how nitric oxide works to control blood pressure. Nitric oxide is a substance in the body that helps blood vessels relax and widen. By studying how these two factors interact, we hope to better understand them, which could lead to improved treatments for patients in the future. However, this study does not provide treatment for patients with heart or blood vessel diseases.
You will be asked to participate in one visit and to receive a medication called sublingual nitroglycerin. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate and blood flow.
You will receive $25 per hour for your participation in this research study
Any race or ethnicity
Men and women age 21- 80 years
Capable of speaking English
blood pressure is <160/100 mmHg
Pregnant or nursing women
Incapable of speaking English
Decisional impairment
Patients with diabetes
Understanding the Media Literacy Competencies of Today’s College Students
This study will involve surveying college students regarding their media literacy competencies and experiences with media literacy education.
18 years of age or older
The perception and experiences of newly diagnosed type 2 diabetes patients (T2D) on the impact of patient-provider communication on subsequent decision to engage in diabetes self-management education (DSME).
This study seeks to explore the perception and experiences of newly diagnosed type 2 diabetes patients about how their interaction with their provider at diagnosis led to their uptake of diabetes education.
Any gender
Newly diagnosed type 2 diabetes patient within the past 12 months
Have attended at least one diabetes education after diagnosis
Able to provide consent in English
Patients who have a different type of diabetes either than type 2
Patients diagnosed with Type 2 diabetes more than 12 months
Newly diagnosed diabetes patients who have not attended diabetes self-management education
Concussion-Prognosis
Using micro-RNA in saliva coupled with survey data as a prognostic tool with the ability to guide clinical management of concussions
During their baseline visit participants will complete a saliva swab, surveys, balance test and brief neurocognitive test. Day 7, participants will complete a saliva swab and 2 surveys. Day 30, participants will complete a saliva swab and 4 surveys. The baseline visit is the only in-person visit, day 7 and day 30 are done remotely. All surveys are completed online and day 7 and day 30 saliva swabs are sent home with the participants and sent back in a prepaid mailer on day 30.
$40
Diagnosis of concussion
Prospective Cohort Assessing Novel Biomarkers of Early Pregnancy
The purpose of this research is to take and store blood, urine samples from pregnant women diagnosed by a positive pregnancy test or by ultrasound imaging. The purpose of this study is to determine a better way to diagnose the location and/or viability (chance of survival) of a pregnancy, as compared to current clinical care. Many women are found to be pregnant by a hCG (human chorionic gonadotropin) test which detects a hormone that is indicative of pregnancy. However, in early pregnancy, it is often difficult to see the pregnancy by ultrasound, which is called a pregnancy of unknown location (PUL). In early pregnancy, doctors do many tests (including blood tests and ultrasounds) to try to determine how far along the pregnancy is, whether it is healthy, and most importantly whether the pregnancy is growing in the right place. The doctors running this research project are trying to see if there are substances (biomarkers) in the blood or urine of a pregnant woman that can tell whether the pregnancy is a normal, healthy pregnancy, an ectopic pregnancy, or if pregnancy is not viable (miscarriage). To do this, blood and/or urine samples are being collected from women who have a pregnancy of unknown location, an ectopic pregnancy, women who are having a miscarriage, and women with a healthy growing pregnancy. The study will then look at a pre- determined panel of biomarkers that have been shown to be elevated (higher) or decreased (lower) in different types of pregnancy to determine the effectiveness and accuracy of this test in earlier diagnosing the viability and location of early pregnancy.
There will be one visit at the visit participants will be consented and following consenting blood and urine will be collected.
$25.00
Live intrauterine pregnancy through 14 weeks, diagnosed by ultrasound demonstrating fetal heart motion
Diagnosed ectopic pregnancy
Pain or bleeding or at risk for ectopic pregnancy
Women seeking confimation of a pregnancy with a urine or serum pregnancy test (less than 14 weeks)
POSTA: Protocol for Oral Somatosensation and Texture Appreciation
The purpose of this study is to collect normative data related to orofacial (lip/tongue) somatosensation (touch sensation) in healthy adults across the adult lifespan. This data will be compared to a select clinical population, those with Parkinson's disease.
There will be one data collection session lasting approximately 90 minutes. Participants may be invited back for a second session approximately 4 weeks later to repeat the testing session During the sessions, participants will answer a series of questions about their eating and drinking preferences, they will be asked to provide a speech sample by repeating a series of syllables, words, and sentences, as well as providing a spontaneous speech sample. All participants will be asked to complete a series of sensory tests where small plastic objects are placed on their lip, tongue, and finger tip. Participants will be asked when they feel the pressure/texture and when they do not.
English-speaking
Hearing and cognition within functional limits to complete speaking tasks
Clinical Group: Diagnosed with Parkinson's disease (PD)
have an active lesion to the lower face (ie cold sore, fever blister, etc)
have had a dental visit in the last month that involved general or local anesthesia to the oral region
exhibit symptoms of Tardive Dyskinesia secondary to anti-psychotic drug use
report current or recovering from a viral illness like Bell’s Palsy or Shingles
Linking olfactory deficits to memory impairment and AD neurodegeneration
The purpose of this voluntary research study is to find out more about changes in the brain as we age. This study is trying to determine if magnetic resonance imaging (MRI), genetic variations, amyloid positron emissions tomography (PET), neuropsychological testing, and smell tests can be used to evaluate memory loss and cognitive impairment.
You will be asked to come to the research site once a year for 5 years. Annual (and semi-annual) procedures include completing smell tests, neuropsychological tests, magnetic resonance imaging (MRI). One-time procedures include provide blood sample, amyloid PET scan (if indicated), and optional lumbar puncture.
Up to $250 a year
Smell impairment
Women who are pregnant or breastfeeding
Currently smoke
Have claustrophobia
The Association Between Head Cooling and Cognition, EEG Patterns, Neuroinflammatory Cytokines, and Mental Health
This research is being done to find out the effects of head cooling on cognition, brain activity as seen in EEG scans, inflammation of the brain, and mood in healthy subjects. What is specifically meant by healthy subjects in the context of this study is subjects who are not currently recovering from a traumatic brain injury.
This study includes an 8-day regimen of head cooling or rest at an average of 30 minutes per day, non-invasive cheek swabs used to collect saliva samples, and non-invasive brain activity testing and questionnaires.
$40
Currently NOT recovering from a brain injury
Currently recovering from a brain injury
Accessibly of Conversational Agents with Deaf or Blind Users
Using small focus groups, this work aims to understand the experiences, challenges, perceptions, and opportunities for the use of conversational agents (e.g Amazon Alexa and Siri) for users with visual or hearing impairments, with the goal of developing more accessible and inclusive systems.
Or, hard of hearing or deaf using cochlear implant or other aided hearing device
Currently 18 years of age or older
English language speakers
Non-English language speakers
Exploring the Immediate Psychosocial and Self-Management Support Needs of Individuals Newly Diagnosed with Type 2 Diabetes (T2D)
To find out the kind of support someone newly diagnosed with type 2 diabetes will need following diagnosis.
Age 20 years or older
agree to participate in online focus group
individuals below 20 years
diagnosed with other types of diabetes
Exploring International Students’ Development of English as a Lingua Franca Pragmatic Competence
This study explores how international students show and develop pragmatic strategies to effectively communicate with peers and colleagues from diverse language and cultural backgrounds at Penn State. Participants recruited from the StudyFinder are invited to complete an online survey, and will receive an Amazon gift card as a token of appreciation.
Pennsylvania Adoptees Longitudinal Study (PALS)
This study will examine various factors within the home of children adopted from the child welfare system between the ages of 4 and 10 that may impact their development. The first visit will occur remotely via Penn State Health Microsoft Teams; the second visit is optional and will occur within 4 weeks of the first visit at the Transforming Lives of Children Center in Harrisburg, PA; and the third visit will occur one year after the first visit, when research staff will travel to participants' homes. This research will help understand the factors that impact the development of children adopted from the child welfare system and how we may better serve these children and their families.
The child and parent will be asked to complete interviews, questionnaires and various tasks. Parents may also be asked to complete questionnaires online. Participation will last for one year and include the following: -One visit occurring remotely via PSH Microsoft Teams -One visit at the Transforming the Lives of Children Center in Harrisburg, PA, four weeks after Zoom visit (optional) -Final visit at home will occur one year after the first Zoom visit
$225
Child legally adopted by the caregiver
The same caregiver will participate in each of the visits
A biological parent resides in the same home as the child
Graduate Students’ Experience with Online Professional Profiles and Social Media
With the development of information and communication technologies, Social Network Sites and other online platforms can be great resources for career-related information and social networking. Despite the evidence of possible professional benefits, it remains unclear whether graduate students’ experiences with building online career profiles and social networking are positive. Therefore, this study aims to understand graduate students’ experience with professional practices on the Internet concerning their motivations, benefits, and risks.
An active graduate student at University Park campus
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This is a multicenter evaluation of seladelpar, administered as a once-daily oral capsule, in a placebo-controlled study in subjects with Primary Biliary Cholangitis (PBC). This study (156 weeks) will enroll approximately 192 subjects. The population to be studied is patients with PBC and compensated cirrhosis restricted to Child-Pugh (CP)-A or CP-B. Primary Objectives Efficacy: To evaluate the effect of seladelpar compared to placebo. Safety: To evaluate the safety of seladelpar over 156 weeks of treatment compared to placebo. Study visits: up to 18 in person visits. Blood samples will be collected at each visit for safety measures as well and questions about your health and medicines you might be taking.
There will be 18 in person visits. safety assessments will be conducted at each visit. Participants will be required to take study drug as directed.
$1350
Elevated Alkaline Phosphatase (ALP)
documented cirrhosis
decompensated cirrhosis
portal vein thrombosis
hospitalization for liver complication within 12 weeks
HIV
Modeling Transition Speeds in Elderly Human Walking
This study will involve elderly humans walking on a treadmill transitioning through prechosen speeds.
There will be one, two hour in person visit. Participants will change into specific lab provided clothing for study and reflective stickers will be placed on participants by the researcher. Participants will then get on the treadmill and will walk at prescribed constant speeds for about 5 minutes total. Then participants will perform 10 speed transition trials each of which lasts about 4 minutes.
$15
Can continuously walk for up to 4 minutes
Be able to follow verbal instructions
High BMI (>30)
Campus Environments and Student Health
The purpose of this study is to learn about the relationship between the campus environment and students’ health. It involves a survey consisting questions about campus-related activities, COVID-19, physical activity and health, environmental perceptions, and demographic information.
There will be an online survey that will take about 20-30 minutes. No need to meet in-person.
At least 18 years old or older
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease
Crohn's disease is a chronic, incurable inflammatory disease of the digestive system. Current treatment advancements need to be improved to meet patient's needs. This study is a 24-week treat-through design (meaning Induction and Maintenance treatment without re-randomization) using either monotherapy (single drug) or combination therapies (two drugs) in moderate to severe Crohn's disease. The participants who are responders will be able to continue treatment in Long Term Extension (LTE) study phase, weeks 24 to 96. This study aims to evaluate the safety and effectiveness of each combination therapy compared to conventional monotherapy.
Subjects will be required to sign the informed consent, and attend in person visits. They will be required to complete daily eDiary, and have tests and procedures done per protocol timeline. Procedures include blood tests, colonoscopies with biopsies, ECG, vitals and physical exam. Pregnancy testing will be done for WOCBP.
$77 per completed visit and $100 for completed endoscopy. Travel will be reimbursed up to $52 for each visit. You will be given $24 for meal if the visit required fasting.
Subjects' body weight must be ≥ 40 kg at
Confirmed diagnosis of CD for at least 3 months
Endoscopic evidence of mucosal inflammation
Intolerance or inadequate response to 1 or more standard treatments including one biologics
Major surgery 3 months prior
Active HBV or HCV infection, TB infection or HIV positive
C. difficile positive or other intestinal pathogen
UC or indeterminate colitis
Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes
The primary aim of this study is to understand taste changes after head and neck cancer treatment, especially long term taste disturbance, using various methods including online surveys, Teams interviews, at home taste and smell tests, and MRIs.
The purpose of this voluntary research study is to identify taste changes in patients treated for head and neck cancer. We are recruiting healthy participants over the age of 40 as well as head and neck cancer survivors who were treated 3 or more years ago. The overall study consists of multiple parts, which are explained along the way. You can choose to participate in this portion, which is an online survey, and nothing else, or all of the invited components. • The survey will take approximately 10 minutes of your time. • Completion of this survey is voluntary and you are not required to complete it if you do not wish to do so. • At the end of the survey you will be asked about your willingness to participate in other portions of this study. These include at-home taste and smell tests over Teams and a Teams interview about your taste and smell function. Participating in these tasks is optional and not required. If you complete the smell and taste tests at home you may be invited to have an MRI scan.
Max of $75: No compensation for the survey, $15 giftcard for 1-hour interview (optional), $15 giftcard for at-home taste/smell tests (optional), $50 giftcard for MRI at Hershey Med Center (optional).
Over the age of 40
English Speaking
have undergone a total glossectomy
currently have an upper respiratory infection, sinus infection, or ear infection